Waypoint Capital Advisors’s Idexx Laboratories IDXX Stock Holding History

Waypoint Capital Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$243K	Sell	480 -12	-2%	-$5.83K	0.05%	118
2024 Q2	$240K	Buy	492 +12	+3%	+$6.02K	0.06%	113
2024 Q1	$259K	Buy	480 +80	+20%	+$43.7K	0.07%	105
2023 Q4	$222K	Buy	+400	New	+$188K	0.06%	111
2023 Q3	–	Sell	-404	Closed	-$203K	–	122
2023 Q2	$203K	Buy	404 +4	+1%	+$1.92K	0.06%	129
2023 Q1	$200K	Buy	+400	New	+$191K	0.07%	130
2022 Q2	–	Sell	-502	Closed	-$275K	–	123
2022 Q1	$275K	Buy	502 +1	+0.2%	+$526	0.16%	98
2021 Q4	$330K	Buy	+501	New	+$315K	0.23%	69

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Waypoint Capital Advisors's IDXX Position: Q3 2024 in Review

Waypoint Capital Advisors reduced its Idexx Laboratories (IDXX) stake by 2.4% in Q3 2024, selling an estimated $5.83K and leaving 480 shares worth $243K. The position accounts for 0.05% of the portfolio, ranked #118.

Waypoint Capital Advisors first reported a position in IDXX in Q4 2021 and has held it in 8 quarters since. The position peaked at $330K in Q4 2021. 1,115 funds tracked by Wall St. Rank hold IDXX as of Q3 2024.

Waypoint Capital Advisors held 480 shares of Idexx Laboratories worth $243K as of Q3 2024.
Waypoint Capital Advisors sold 12 Idexx Laboratories shares in Q3 2024, an estimated $5.83K.
Idexx Laboratories made up 0.05% of Waypoint Capital Advisors's portfolio in Q3 2024, its #118 holding.
Waypoint Capital Advisors first reported a position in Idexx Laboratories in Q4 2021 and has held it in 8 quarters since.
Waypoint Capital Advisors's Idexx Laboratories position peaked at $330K in Q4 2021.
1,115 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2024.

Based on Waypoint Capital Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.